Picard Medical Secures Shareholder Approval for Major Capital Expansion Amid Legal Challenges

Picard Medical shareholders approve major capital increase for flexibility, as the firm faces investor lawsuits over alleged stock manipulation and celebrates a key artificial heart success.

Picard Medical finds itself navigating a complex landscape where groundbreaking medical achievement intersects with significant legal and financial scrutiny. The company's recent shareholder meeting has paved the way for a substantial strengthening of its balance sheet, even as it confronts serious allegations from investors.

Shareholders Endorse Capital Restructuring

During a virtual general meeting, Picard Medical's investors granted crucial approvals for a comprehensive overhaul of the company's equity foundation. The formal authorization was given to increase the authorized share capital from 180 million to 330 million shares, representing a near-doubling of capacity. Furthermore, shareholders consented to the issuance of additional securities tied to an existing equity purchase agreement.

This strategic move is designed to provide the firm with enhanced financial flexibility for its future operations. However, it has simultaneously sparked market concerns regarding the potential dilution of current shareholdings. Market observers are now closely monitoring the company's next steps, particularly the timing and terms under which this newly authorized capital will be deployed.

Operational Milestone Offers Counterpoint

Amid the financial and legal developments, Picard Medical continues to progress on the clinical front. In a significant achievement, a patient successfully received a transplant in late February 2026 after being supported for several years by the company's artificial heart system. This technology acts as a bridge to transplant and currently holds the distinction of being the only commercially approved device of its kind in both the United States and Canada.

This medical success stands in contrast to the other pressures facing the company, offering a tangible result from its research and development efforts.

Legal Allegations Cast a Shadow

Concurrent with its corporate restructuring, Picard Medical is facing a surge of collective legal actions. Several law firms have initiated proceedings related to a period between September and October 2025. The allegations are substantial, centering on suspicions that the company may have participated in a coordinated scheme to artificially influence its stock price.

Plaintiffs contend that information was disseminated through social media channels to inflate trading volume artificially. A particularly serious accusation suggests that insiders may have sold shares via offshore accounts during the period in question. For affected investors, critical deadlines are approaching; they have until early to mid-April 2026 to apply for lead plaintiff status in these ongoing proceedings.

Path Forward Hinges on Transparency and Trust

The coming weeks will prove decisive for Picard Medical. The immediate focus, leading up to mid-April 2026, involves the formal legal organization of the collective lawsuits. At the same time, the company must demonstrate that it will utilize its newly approved capital structure in a manner that is both transparent and aligned with shareholder interests. This will be essential to counter allegations concerning a lack of openness.

Ultimately, the company's ability to rebuild investor confidence may depend on whether its operational successes in the medical field can outweigh the current financial uncertainties and legal disputes.